Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy

Trial Details

NCT ID

NCT07309185

Phase

PHASE2

Sponsor

Shandong Tumor Hospital

Status

RECRUITING

Cancer Type

Gastric Cancer

Interventions

• Adebrelimab
• Irinotecan
• Malic acid Famitinib

Locations (sample)

• Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

• 1\. Patients with advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma diagnosed by histology or cytology;
• 2\. Patients who have previously failed first-line treatment including systemic chemotherapy and immune checkpoint inhibitors, and have maintained …
• 3\. According to the evaluation criteria for solid tumor efficacy 1.1 (RECIST v1.1), there should be at least one measurable lesion that has not re…
• 4\. ECOG score: 0-1 point;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.